Clinical response to primary letrozole therapy in elderly patients with early breast cancer: Possible role for p53 as a biomarker  by Garimella, Veerabhadram et al.
lable at ScienceDirect
International Journal of Surgery 12 (2014) 821e826Contents lists avaiInternational Journal of Surgery
journal homepage: www.journal-surgery.netOriginal researchClinical response to primary letrozole therapy in elderly patients with
early breast cancer: Possible role for p53 as a biomarker
Veerabhadram Garimella a, b, 1, Tasadooq Hussain a, b, d, 1, Vijay Agarwal a, c, d, 1,
Selvi Radhakrishna a, b, John N. Fox b, Peter J. Kneeshaw b, Ervine D. Long e,
Tapan K. Mahapatra b, Penelope L. McManus b, Michael J. Lind a, c, d, Philip J. Drew a, b, d,
Lynn Cawkwell a, d, *
a Postgraduate Medical Institute of the University of Hull, Hull, UK
b Breast Care Unit, Hull and East Yorkshire NHS Trust, Hull, UK
c Queens Centre for Oncology and Haematology, Hull and East Yorkshire NHS Trust, Hull, UK
d Hull York Medical School, Hull, UK
e Histopathology Department, Hull and East Yorkshire NHS Trust, Hull, UKh i g h l i g h t s Primary endocrine therapy can be used to control breast cancer.
 Letrozole therapy compared to anastrazole and tamoxifen has shown better objective response rates.
 This study provides a 5 year follow up data on patients treated with primary endocrine therapy using letrozole.
 Biomarkers to letrozole therapy response and to predict patient prognosis can be a useful tool in patient selection.
 The study ﬁndings suggest p53 may be a useful protein biomarker to facilitate patient selection to letrozole therapy.a r t i c l e i n f o
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Primary tamoxifen therapy has been widely used to treat elderly women with ER-positive breast cancer
in the past. Aromatase inhibitors may be more beneﬁcial than tamoxifen when used as primary endo-
crine therapy in elderly patients. We aimed to retrospectively evaluate a series of elderly women with
ER-positive breast cancer treated with primary letrozole therapy as sole therapy with a minimum of 5
years follow up. To identify possible predictive biomarkers a pilot immunohistochemical analysis was
performed to assess the expression of PR, HER2, EGFR, BCL2 and p53.
A total of 45 women, aged more than 70 years with a diagnosis of ER-positive breast cancer that was
treated with primary letrozole therapy were identiﬁed. A case note review was undertaken to obtain
clinical information. Formalin ﬁxed parafﬁn embedded tumour tissue from diagnostic core biopsies was
available for all patients. Immunohistochemical analysis was performed to establish the protein
expression status of p53, PR, HER2, EGFR and BCL2.
The mean age of the 45 patients was 87 years (range 70e101). Clinical beneﬁt was seen in 60% of the
patients. Median progression free survival was 53 months (95% CI e 34e72) and the median time to
progression was 43 months (95% CI e 22e64). BCL2 was expressed in 45/45 (100%); PR in 38/45 (84%);
EGFR in 13/45 (28%); HER2 in 9/45 (20%) and p53 in 5/45 (11%) of tissue samples. Positive expression of
p53 was associated with poor progression free survival (p ¼ 0.03) in this pilot study.
This study demonstrates that letrozole as sole treatment appears to be a suitable treatment option for
elderly patients with ER-positive breast cancer who are not ﬁt for, or decline, surgery. The analysis of p53
in a larger study is warranted in order to assess its role as a biomarker in this patient group.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Hospital, Hull HU16 5JQ, UK.
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V. Garimella et al. / International Journal of Surgery 12 (2014) 821e8268221. Introduction post-menopausal women and demonstrated that the overallBreast cancer is one of the most common cancers worldwide,
with more than one third of them occurring in women over 70
years of age in the UK [1]. In this cohort (>70 years), breast cancer
predominantly present as palpable cancers (mostly T2-4) and are
frequently hormone receptor positive [2e7]. In the absence of
clinical recommendations, treatment of women in this age group
has often been based upon studies conducted in younger patients,
since few women over the age of 65 are recruited into major trials
[1,7,8].
Primary tamoxifen therapy has beenwidely used to treat elderly
women with ER-positive breast cancer in the past. However, a
recent Cochrane systematic review of 6 randomized control trials
(n ¼ 157; events 869) has shown that primary surgery (with or
without adjuvant endocrine therapy) resulted in better progression
free survival (PFS) compared to tamoxifen, but there was no dif-
ference in overall survival [9]. A randomized control trial in the UK
comparing surgery plus tamoxifen versus tamoxifen alone in 455
women over 70 years of age with a median follow up of more than
12 years showed the surgery plus tamoxifen treatment arm to have
longer time to treatment failure and improved survival (overall
mortality andmortality from breast cancer) compared to tamoxifen
alone [10]. The Italian phase III randomized GRETA trial compared
surgery plus adjuvant tamoxifen (n ¼ 239) to primary tamoxifen
alone (n ¼ 235) in women over 70 years of age with breast cancer
and demonstrated no beneﬁt in the overall survival or breast cancer
survival, but improved rates of local progression in the surgery plus
tamoxifen treatment arm compared to tamoxifen alone
(p ¼ 0.0001) [11]. Furthermore, clinical results from three major
trials (CRC, GRETA and Nottingham 2 study) that looked into the
role of surgery plus adjuvant endocrine treatment to primary
endocrine treatment alone indicate the overall survival (OS) for the
primary endocrine treatment is comparable to the surgery plus
adjuvant treatment arm (Table 1).
Aromatase inhibitors (AI's) such as letrozole, anastrozole or
exemestane may be more beneﬁcial than tamoxifen when used as
primary endocrine therapy in elderly patients. Letrozole has been
shown to be beneﬁcial in older patients in two large adjuvant trials,
MA.17 and BIG 1-98 [12e14] and the use of AI's for primary therapy
in post-menopausal womenwith ER-positive breast cancer has also
shown promising results in various trials (Table 2). The P024 trial
compared 4 months of pre-operative tamoxifen versus letrozole inTable 1
Surgery plus adjuvant endocrine therapy vs primary endocrine therapy.
Trial Median
follow up
Surgery (n/N) Primary endocrine
therapy (n/N)
HR (95% CI)
Surgery plus endocrine therapy vs primary endocrine therapy
Mortality (OS)
CRC 13 years 159/225 187/230 0.78 (0.63e0.98)
GRETA 7 years 130/239 144/235 0.98 (0.77e1.25)
Nottingham 2 5 years 8/53 14/94 0.80 (0.73e2.32)
Progression free survival (PFS)
CRC 13 years NR NR NR
GRETA 7 years 14/239 188/235 0.65 (0.53e0.81)
Nottingham 2 5 years NR NR NR
Local progression (LR) or LR as ﬁrst event
CRC 13 years 36/225 115/230 0.25 (0.19e0.32)
GRETA 7 years 27/239 95/235 0.38 (0.25e0.57)
Nottingham 2 5 years 2/53 30/94 Not estimable
The above table summarises the ﬁndings of surgery plus adjuvant endocrine
treatment versus primary endocrine treatment alone from the three important
randomised controlled trials. In all the three trials, the overall survival (OS) for the
primary endocrine treatment arm was found similar to surgery and adjuvant
treatment arm (Hind D et al. Br J Cancer. 2007 Apr 10; 96(7):1025e9).response to letrozole was signiﬁcantly better than tamoxifen (55%
versus 36%; p ¼ 0.001) and resulted in increased breast-conserving
surgery (45% versus 35%; p ¼ 0.022) [15,16]. Other studies such as
The IMPACT trial and the PROACT trial compared pre-operative
treatment with anastrozole versus tamoxifen and showed that
there was no statistically signiﬁcant difference between anas-
trozole and tamoxifen in overall response and rates of breast-
conserving surgery [17,18]. In a study of elderly patients with ER-
positive breast cancer treated with either primary tamoxifen or
anastrozole no signiﬁcant difference in clinical beneﬁt between the
two groups was identiﬁed [19]. Two small phase II trials found that
the use of exemestane as primary therapy was effective in post-
menopausal women with ER-positive breast cancer and was a
feasible therapy option for elderly patients [20,21]. Recent recom-
mendations for the management of elderly breast cancer patients
include the use of primary tamoxifen or AI therapy in unﬁt patients
with short life expectancy or for those who refuse surgery [7].
To further increase the efﬁcacy of AI's as primary or neoadjuvant
treatment in breast cancer, the identiﬁcation of predictive bio-
markers of response and improved survival is paramount. In the
P024 trial, letrozole showed similar efﬁcacy when administered to
patients with HER2-positive, HER2-negative, EGFR-positive and
EGFR-negative tumours. However, ER-positive patients who
demonstrated double positivity for EGFR and HER2 had higher
response rates to letrozole therapy compared to patients who were
double negative (88% versus 54%; p ¼ 0.018) [22]. In a similar study
using anastrazole, HER2 status was not associated with response to
treatment [23]. In another study of 305 patients, which included
patients from the P024 study as well as from the Edinburgh Breast
Unit, response to letrozole was seen irrespective of the HER2 status
which was assessed by FISH [24]. In a study involving elderly pa-
tients treated with primary anastrazole treatment, HER2 positivity
was associated with shorter PFS (p¼ 0.003) whilst EGFR expression
was not associated with survival [19]. Further data on the use of
primary AI therapy in the treatment of elderly patients with ER-
positive breast cancer is required.2. Aims of the study
We aimed to retrospectively evaluate a series of elderly women
with ER-positive breast cancer treated at our Breast Unit with pri-
mary letrozole therapy as sole therapy and with a minimum of 5
years follow up. To further identify possible predictive biomarkers
of response, a pilot immunohistochemical analysis was performed
to assess the tumour expression of PR, HER2, EGFR, BCL2 and p53.3. Methods
Following approval by Hull and East Riding Research Ethics
Committee, retrospective data was assessed from elderly patients
(age >70 years) who had received primary letrozole therapy for ER-
positive breast carcinoma between 2002 and 2004. Diagnostic core
biopsies and clinical information was required for all patients. A
case note review was undertaken to obtain information regarding
tumour characteristics, response to therapy and disease progres-
sion. All patients had undergone triple assessment including clin-
ical examination, mammogram, ultrasound scan and histological
assessment of core biopsy samples to establish the diagnosis of
breast cancer. Each case had been discussed at a multidisciplinary
team meeting before patients were offered the treatment options.
Primary letrozole therapy was employed for ER/PR positive elderly
patients with signiﬁcant co-morbidity or those who had declined
surgery. All patients received clinical followed up at three monthly
Fig. 1. The study consort. Consort chart for the pilot study showing a total of 110
patients who were treated with letrozole as primary therapy as identiﬁed from the
prospectively maintained chemotherapy database. After case note review, 41 patients
were excluded from the study as they had metastatic disease at presentation, refused
follow up after their ﬁrst visit or they chose early surgery without completing the
treatment course. Of the 69 remaining patients, 45 patients had core biopsy samples
available for assessment.
Table 2
Aromatase inhibitor trials.
Trial Patient number (n) Comparator ORR BCS
P024 (Eiermann 2001) n ¼ 337 Letrozole Tamoxifen 55% vs 36% 45% vs 35%
P ¼ <0.001 P ¼ 0.022
IMPACT (Smith 2005) n ¼ 330 Anastrazole Tamoxifen 37% vs 36% 44% vs 31%
P ¼ 0.87 P ¼ 0.23
PROACT (Cataliotti 2006) n ¼ 451 Anastrazole Tamoxifen 40% vs 35% 38% vs 30%
P ¼ 0.29 P ¼ 0.11
(Semiglazov 2007) n ¼ 239 Anastrazole/Exemestane Chemotherapy 65% vs 64% 33% vs 24%
P ¼ >0.5 P ¼ 0.58
The above table shows ﬁndings from the four major aromatase inhibitor trials namely P024, IMPACT, PROACT and Semiglazov study. Of the four trials, three compared
anastrozole with standard tamoxifen and/or chemotherapy treatment and one trial compared letrozole with tamoxifen for attainment of objective response (ORR) and breast-
conserving surgery (BCS) rates. Findings from the studies clearly demonstrate letrozole to be the superior therapy to attain ORR and BCS rates compared to other AIs and
chemotherapy.
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metastases other treatment options had been discussed with the
patient.
3.1. Endocrine therapy
All elderly post-menopausal patients with early breast cancer
not ﬁt for surgery were treated with letrozole 2.5 mg daily as ﬁrst
line agent.
3.2. Assessment of efﬁcacy
Clinical end points such as PFS, time to progression (TTP) and
response rate were calculated. PFS was deﬁned as the time from
biopsy until tumour progression or death due to any cause. As a
signiﬁcant number of patients in this cohort had died due to causes
unrelated to breast cancer TTP was also calculated and deﬁned as
the time from biopsy until tumour progression. Progressive disease
was deﬁned as an increase in the primary breast tumour size by
clinical caliper examination of more than 20% or development of
metastatic disease. Clinical beneﬁt was deﬁned when tumour
response or stable disease was achieved following treatment.
3.3. Immunohistochemistry
Formalin ﬁxed, parafﬁn embedded core biopsies taken at the
time of breast cancer diagnosis were retrieved for 45 tumours.
Immunohistochemical results for ER and PR, performed at the time
of diagnosis and scored according to the method of Allred [25],
were obtained from histology reports. Immunohistochemical
staining for BCL2, EGFR, HER2 and p53 was carried out using an
avidin-biotin complex protocol described previously [26,27]. In
brief, antigenic sites were retrieved by boiling in a 1:100 Antigen
Unmasking Solution (Vector Laboratories Ltd) in a pressure cooker
for 3 min at 15 psi. Non-speciﬁc binding was blocked with 1
casein (Vector Laboratories Ltd) and endogenous avidin and biotin
were blocked by 15 min incubations with biotin and avidin,
respectively (Avidin Biotin Blocking Kit, Vector Laboratories Ltd).
Sections were incubated at room temperature for 2 h with primary
antibody. A ﬁnal dilution of 1:50 was used for BCL2 (#MS-123,
Neomarkers) and EGFR (#MS-316, Neomarkers). A ﬁnal dilution of
1:100 was used for p53 (#554293, BD Biosciences). HER2 (#NCL-L-
CBE-356, Novocastra Vision Biosystems) was used at 1:50 without
heat retrieval. A negative control was also included in each batch of
slides, in which the primary antibody was omitted. The slides were
scored by 2 independent investigators. Sections were scored posi-
tive for p53 expression if strong clonal immunoreactivity was
observed in greater than 10% of tumour nuclei and positive for the
anti-apoptotic protein BCL2 if strong expressionwas seen in greaterthan 10% of tumour cytoplasm as previously described [27]. Simi-
larly, sections were scored positive for EGFR and HER2 if strong
cytoplasmic/membrane expression was observed in greater than
10% of malignant cells.
3.4. Statistical analysis
Statistical analysis was performed using SPSS software version
19.0 (SPSS, Chicago, USA). PFS and TTPwere estimated using Kaplan
Meier curves. Univariate survival analysis was performed for
biomarker expression using Kaplan Meier curves with log rank
analysis. Fisher's exact test was performed to assess biomarkers
predictive of response to letrozole. A two tailed p-value of <0.05
was considered to be statistically signiﬁcant.
4. Results
The patient characteristics in the study are described in Fig. 1. A
total of 45 patients' core biopsies were analysed using IHC. This
sample represents 3% (45/1450) of all the breast cancers treated at
our institution during the three year study period. The median age
of study patients was 87 years (range 70e101). Triple assessment
V. Garimella et al. / International Journal of Surgery 12 (2014) 821e826824revealed a clinical tumour stage T2 or greater in 66% (30/45) of
cases. Histological characteristics revealed that the majority (57%;
26/45) of tumours were of non-speciﬁc subtype. Invasive ductal
carcinoma represented 37% (17/45) of cases and invasive lobular
carcinoma represented 4% (2/45) of cases.4.1. Follow up, response and survival to primary letrozole therapy
All patients were followed up for a minimum of 5 years, with a
median follow up period of 92 months (range 4e106 months). All
patients during the FU were evaluated by clinical examination.
Clinical beneﬁt was seen in 60% (27/45) of the patients and 40% (18/
45) of patients had progressed on letrozole therapy. At the end of
last follow up, 68% (31/45) of the patients had died. The median PFS
was 53 months (95% CI e 34e72) and the median TTP was 43
months (95% CI e 22e64).4.2. Molecular markers predicting response or improved survival to
primary letrozole therapy
The expression of BCL2 was seen in 100% (45/45) of the tumour
samples. The expression of PR was seen in 84% (38/45) of cases;
EGFR in 28% (13/45); HER2 in 20% (9/45) and p53 in 11% (5/45). In
this pilot study p53 staining was used as a surrogate to identify p53
gene mutation. In a univariate analysis, the positive expression of
p53 was signiﬁcantly found associated with a poor PFS (median
survival 20 months versus 54 months in p53 negative; p ¼ 0.03;
Fig. 2). Clinical beneﬁt was seen in only 1 out of 5 patients har-
bouring a p53-positive tumour. The expression of PR, EGFR and
HER2 was not associated with survival. Correlation of protein
expression with treatment response using Fishers exact test was
not statistically signiﬁcant.Fig. 2. Kaplan Meier plot showing univariate analysis of p53 expression (p ¼ 0.03, log rank).
months for p53-negative cases (n ¼ 40; solid line).5. Discussion
In this study, we have described a series of 45 elderly patients
with ER-positive breast cancer who were treated with primary
letrozole therapy and followed up for a minimum period of 5 years.
Our study demonstrated clinical beneﬁt in 60% of the patients, with
40% having progressed on letrozole at last follow up or death. There
are few published reports describing the clinical experience of
using primary letrozole therapy in elderly breast cancer patients. A
previous case series from the Edinburgh Breast Unit reported their
ﬁndings from 182 post-menopausal patients, of whom 63 had
continued on primary letrozole therapy beyond 3 months [28]. The
median follow up of this study was 3 years and disease control was
achieved in over 70% of the 63 patients using letrozole. Another
recently published retrospective study evaluated the overall sur-
vival and response rate of 104 elderly patients with ER/PR-positive
breast cancer who were treated with primary letrozole therapy
[16]. Some of the earlier described studies using tamoxifen as the
primary hormone therapy showed disease progression and poor
survival after two years even in patients who initially responded to
treatment. In contrast, ﬁndings from our study showed only one
patient progressed within the ﬁrst year and four more within two
years of commencing treatment (11%; 5/45).
Previously, breast cancer studies in elderly evaluated the role of
p53, HER2 and EGFR as potential biomarkers of therapy responses
and prognosis with trends towards less frequent overexpression of
biomarkers favouring an improved survival and more desirable
tumour biology [5,22,24,29,30]. Our pilot study showed similar
trend of low frequency of overexpression of these protein markers.
Previously, HER2 positivity has been demonstrated to associate
with shorter PFS in elderly patients who received primary anas-
trazole therapy [19]. However, in our pilot study, we found p53
expression as a surrogate for mutation status which was found to
be associated with poor PFS. From the above ﬁndings, weThe median survival was 20 months in p53-positive cases (n ¼ 5; dotted line) versus 54
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patients for primary letrozole therapy. Mutations in p53 may result
in a stable p53 protein that can be identiﬁed by immunohisto-
chemistry, however not all mutations are associated with stabilised
protein [31]. Further studies using DNA sequencing-basedmethods,
may therefore also be required to assess p53 mutation status in
order to validate the effect of p53 mutation on PFS in patients
treated with letrozole as primary therapy.
The study has certain limitations. For an exploratory nature, the
patient numbers are small and the study is under-powered. How-
ever, despite the above limitation, a clear statistical difference was
found for p53 in the responder group. The other biomarkers BcL-2,
EGFR and HER2 failed to reach a statistical signiﬁcance, the later
ﬁnding explained due to a type 2 statistical error from a small pa-
tient cohort analysed. Further, the study explores the potential of
p53 as a screening tool for therapy selection rather limitedly as only
65% (45/69) of core biopsy samples from 69 potentially eligible
patients were analysed in the immuno-histo-chemical studies.
Finally, only a small proportion of patients (0.3%; 5/1450; 11% of 3%)
from the study group were shown to beneﬁt from using p53 as a
therapy biomarker and therefore larger studies evaluating the role
of p53 in primary endocrine therapy are now required.
6. Conclusion
In conclusion, our pilot study demonstrated that the positive
expression of p53 was associated with poor PFS in patients treated
with primary letrozole therapy. This biomarker may be used as a
useful screening tool to select patients who would beneﬁt from
primary letrozole therapy.
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